Selective cytotoxic activity of the marine-derived batzelline compounds against pancreatic cancer cell lines

Anti-Cancer Drugs

Volumn 20, Issue 2, 2009, Pages 149-155

  Guzmán, Esther A ^a,b   Johnson, Jacob D ^a   Carrier, Megan K ^a   Meyer, Cara I ^a   Pitts, Tara P ^a   Gunasekera, Sarath P ^a   Wright, Amy E ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Drug discovery; Mechanism of action; Natural products; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BATZELLINE A; BATZELLINE B; BATZELLINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); ISOBATZELLINE A; ISOBATZELLINE C; ISOBATZELLINE D; ISOBATZELLINE E; PYRROLOIMINOQUINONE DERIVATIVE; SECOBATZELLINE A; SECOBATZELLINE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; VERO CELL;

ALKALOIDS; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXINS; DNA; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; INTERCALATING AGENTS; PANCREATIC NEOPLASMS; PORIFERA; PYRROLES; PYRROLOIMINOQUINONES; QUINOLINES; SUBSTRATE SPECIFICITY;

EID: 59449097003     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32831fa39e     Document Type: Article

References (15)

1. All about pancreatic cancer. American Cancer Society 2008.
2. Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer R Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 2006; 11:612-623.
3. Bergenfeldt M, Albertsson M. Current state of adjuvant therapy in resected pancreatic adenocarcinoma. Acta Oncol 2006; 45:124-135.
4. Sun HH, Sakemi S, Burres N, McCarthy PJ. Isobatzellines A, B, C and D. Cytotoxic and antifungal pyrroloquinoline alkaloids from the marine sponge batzella sp. J Organic Chem 1990; 55:4964-4966.
5. Gunasekera SP, McCarthy PJ, Longley RE, Pomponi SA, Wright AE. Secobatzellines A and B, two new enzyme inhibitors from a deep-water Caribbean sponge of the genus Batzella. J Nat Prod 1999; 62:1208-1211.
6. Chang LC, Otero-Quintero S, Hooper JN, Bewley CA. Batzelline D and isobatzelline E from the Indopacrfic sponge Zyzzya fuliginosa. J Nat Prod 2002; 65:776-778.
7. Antunes EM, Copp BR, Davies-Coleman MT, Samaai T. Pyrroloiminoquinone and related metabolites from marine sponges. Nat Prod Rep 2005; 22:62-72.
8. Barrows LR, Radisky DC, Copp BR, Swaffar DS, Kramer RA, Waiters RL, et al. Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors. Anticancer Drug Des 1993; 8:333-347.
9. Matsumoto SS, Haughey HM, Schmehl DM, Venables DA, Ireland CM, Holden JA, et al. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction. Anticancer Drugs 1999; 10:39-45.
10. Dijoux MG, Schnabel PC, Hallock YF, Boswell JL, Johnson TR, Wilson JA, et al. Antitumor activity and distribution of pyrroloiminoquinones in the sponge genus Zyzzya. Bioorg Med Chem 2005; 13:6035-6044.
11. Kuo PL, Hsu YL, Kuo YC, Chang CH, Lin CC. The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anticancer Drugs 2005; 16:789-795.
12. Giles Gl, Sharma RP. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem 2005; 1:383-394.
13. Larsen AK, Escargueil AE, Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 2003; 5:295-300.
14. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg 2006; 10:207-214.
15. McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 2007; 623:83-97.